| Q33485538 | A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder |
| Q54064828 | Alpha-2-adrenoceptor control of cortisol and ACTH in normal volunteers: preliminary open trial of the effects of acute and chronic idazoxan. |
| Q34700305 | An eight-week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia |
| Q50532427 | Anterior Cingulate Implant for Alcohol Dependence: Case Report. |
| Q45249086 | Anti-anxiety drugs reduce conflict-specific "theta"--a possible human anxiety-specific biomarker |
| Q99232790 | Anxiolytic effects of acute and maintenance ketamine, as assessed by the Fear Questionnaire subscales and the Spielberger State Anxiety Rating Scale |
| Q33696575 | Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir |
| Q51160815 | Benzodiazepine receptor sensitivity in panic disorder. |
| Q24197945 | Benzodiazepines for generalised anxiety disorder (GAD) |
| Q46497127 | Bioavailability of amlodipine besylate following oral administration as a tablet dispersed in applesauce |
| Q80142362 | Bioavailability of amlodipine besylate/atorvastatin calcium combination tablet |
| Q35235578 | Challenge tests: assessment of the noradrenergic and GABA systems in depression and anxiety disorders |
| Q41673269 | Changes in serum hepatitis C virus RNA in interferon nonresponders retreated with interferon plus ribavirin: a preliminary report |
| Q22252432 | Comparative efficacy and acceptability of mood stabilizer and second generation antipsychotic monotherapy for acute mania — A systematic review and meta-analysis |
| Q83617016 | Comparative efficacy of anti-manic drugs in acute mania |
| Q37555366 | Comparative efficacy of antidepressants in preventing relapse in anxiety disorders - a meta-analysis |
| Q35183615 | Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers |
| Q33630473 | Cytochrome P450 enzymes and drug metabolism--basic concepts and methods of assessment |
| Q48272087 | Dose- and exposure-response to ketamine in depression |
| Q71006669 | Effect of felbamate on valproic acid disposition in healthy volunteers: inhibition of beta-oxidation |
| Q80305695 | Effect of food on the bioavailability of amlodipine besylate/atorvastatin calcium combination tablet |
| Q34976469 | Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials |
| Q71809390 | Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive |
| Q71731576 | Effects of felbamate on the pharmacokinetics of phenobarbital |
| Q90127954 | Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study |
| Q46107330 | Effects of standard and supratherapeutic doses of nelfinavir on cardiac repolarization: a thorough QT study |
| Q51350979 | Evaluation of bioequivalence between clozapine suspension and tablet formulations : a multiple-dose, fed and fasted study. |
| Q43813172 | Factors associated with hospitalization of adult psychiatric patients: cluster analysis. |
| Q37471054 | Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite |
| Q102202056 | Influence of formulation and route of administration on ketamine's safety and tolerability: systematic review |
| Q47909182 | Intestinal absorption of ribavirin is preferentially mediated by the Na+-nucleoside purine (N1) transporter |
| Q96306676 | Ketamine and neuroticism: a double-hit hypothesis of internalizing disorders |
| Q44026920 | Lactate-induced electrolyte changes in the cerebrospinal fluid of rabbits |
| Q49076879 | Lithium treatment effect on serotonin function |
| Q93262805 | Low-risk and high-risk groups matter in suicide risk |
| Q37773366 | Meta-analysis of relapse prevention antidepressant trials in depressive disorders |
| Q36830686 | Model-based drug development |
| Q48341035 | Monoamines and alcohol |
| Q48173177 | Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer |
| Q35997293 | Optimal treatment of social phobia: systematic review and meta-analysis |
| Q68847420 | Oxytocin and vasopressin responses to ECT |
| Q30620502 | Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group |
| Q42283777 | Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers |
| Q36536413 | Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects |
| Q80306550 | Pharmacokinetics of an extended release formulation of alprazolam (Xanax XR) in healthy normal adolescent and adult volunteers |
| Q51564910 | Pharmacokinetics of dexrazoxane in subjects with impaired kidney function. |
| Q50554702 | Pharmacokinetics, safety, and tolerability of ribavirin in hemodialysis-dependent patients. |
| Q44129882 | Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C. |
| Q43000537 | Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. |
| Q33628834 | Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial |
| Q38743385 | Psychosurgery Reduces Uncertainty and Increases Free Will? A Review |
| Q52065167 | Rapid cycling affective disorders in the mentally retarded. |
| Q67653235 | Regional neurotransmitter responses after acute and chronic electroconvulsive shock |
| Q35802787 | Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions |
| Q50583979 | Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models. |
| Q35027450 | Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters |
| Q96305012 | Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: open label pilot study |
| Q80376499 | Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial |
| Q33155841 | Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects |
| Q44167269 | Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction |
| Q35825645 | Single-dose pharmacokinetics and tolerability of pegylated interferon-alpha2b in young and elderly healthy subjects |
| Q37858609 | Study design and patient characteristics and outcome in acute mania clinical trials |
| Q48311153 | Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder |
| Q42553398 | The effect of age on the apparent clearance of felbamate: a retrospective analysis using nonlinear mixed-effects modeling |
| Q28472672 | The effect of azithromycin on ivermectin pharmacokinetics--a population pharmacokinetic model analysis |
| Q48411472 | The effect of lithium on 5-HT-mediated neuroendocrine responses and platelet 5-HT receptors |
| Q46233521 | The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial. |
| Q43241662 | The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing |
| Q36055167 | The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease |
| Q79881692 | Thorough QT study with recommended and supratherapeutic doses of tolterodine |
| Q42655585 | Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism |